The Caris Precision Oncology Alliance™ (POA) convenes the brightest minds in oncology, cancer care, clinical research, and drug development. The vision statement of the POA is to build the best-in-class collaborative research network focusing on precision oncology to identify predictive and prognostic markers that help in improving the outcomes and clinical care of patients with cancer. The POA aims to deliver molecular science solutions to promote clinical trials that cultivate combined clinical-genomic data and collaborative research to advance the science of cancer care. The alliance is comprised of a growing network of leading cancer centers from across the country that demonstrate a commitment to precision medicine and work collaboratively to:
It’s important for oncologists and patients to know that their data is available to them for analysis. Our database of clinical outcomes is populated with anonymized data from POA member institutions and from commercially available data. This continuous feedback loop between finding new biomarkers and interpreting their significance, provides insights for drug developers, which ultimately feeds back into our system and directly helps patients.
In addition to creating a thought leadership network to develop best practices and guidelines for integrating molecular profiling into patient treatment management, POA members:
The Caris Precision Oncology Alliance™ (POA) Executive Committee establishes appropriate molecular testing principles to serve as guidelines for the consistent application of tumor profiling across the oncology community. The Executive Committee facilitates collaborative research studies across the POA and coordinates outcome tracking initiatives to generate and document additional medical evidence for the appropriate use and impact of profiling. The Executive Committee of the POA serves as a resource to Caris leadership helping to drive research strategy and direction.
Chairman, Precision Oncology Alliance
Chief, Division Hematology and Oncology, Department of Medicine, Professor of Medicine and Oncology, Georgetown University
Associate Center Director for Translational Sciences,
Karmanos Cancer Institute
Associate Director for Clinical Research, USC Norris Comprehensive Cancer Center
University of Cincinnati Cancer Institute and The Barrett Cancer Center
Associate Dean for Oncologic Sciences, Brown University
Executive Director, University of Puerto Rico Comprehensive Cancer Center
POA Tumor Groups
The POA Tumor Groups identify leadership opportunities, author publications, and develop protocols.
Geoff Gibney, MD
Co-leader, Melanoma Disease Group,
Lombardi Comprehensive Cancer Center and MedStar Cancer Network
The Caris Precision Oncology Alliance™ consists of leading cancer centers around the world that are committed to precision medicine and work collaboratively to advance the delivery of molecular testing and establish standards of care for profiling solid tumors.
Every day, new discoveries confirm the increasing and important role biomarker analysis and tumor profiling have in personalized cancer care. We contribute to the body of research in oncology to advance the understanding of molecular science and further enable the delivery of precision medicine.